KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings (2019 - 2025)

Royalty Pharma's Retained Earnings history spans 7 years, with the latest figure at $2.4 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 17.2% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $2.4 billion, down 17.2%, while the annual FY2025 figure was $2.4 billion, 17.2% down from the prior year.
  • Retained Earnings for Q4 2025 was $2.4 billion at Royalty Pharma, up from $2.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.8 billion in Q4 2024 and bottomed at $16.9 million in Q3 2022.
  • The 5-year median for Retained Earnings is $2.3 billion (2021), against an average of $2.0 billion.
  • The largest annual shift saw Retained Earnings crashed 99.27% in 2022 before it surged 12528.25% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $2.3 billion in 2021, then fell by 12.88% to $2.0 billion in 2022, then rose by 28.14% to $2.5 billion in 2023, then grew by 13.03% to $2.8 billion in 2024, then fell by 17.2% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Retained Earnings are $2.4 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.2 billion (Q2 2025).